Maintained by Sreepriya Prasannan

MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist

Compiled from ClinicalTrials.gov and CTIS registry records · Last verified 26 Sep 2026 · Editorial standards

At a glance

The First Hospital of Jilin University is the lead sponsor of 47 current clinical trials in our China register. 30 are recruiting patients now. The most common phase is Observational. The drugs named most often in its trials are Sintilimab, Chidamide and Bendamustine. The most-studied condition is Rectal Cancer.

ClinicalTrials.gov trials by status

Recruiting3064%
Not yet open817%
Active, closed511%
By invitation49%

Trials by phase

Observational1634%
Not applicable1430%
Phase 21123%
Phase 436%
Phase 2/312%
Phase 112%
Phase 1/212%

Clinical trials sponsored by The First Hospital of Jilin University

47 on ClinicalTrials.gov

Study	Phase	Status	Start	Registers
Observational Clinical Study on Role of MRD in Predicting Local Therapy in Oligometastatic Breast Cancer NCT06918262 · ClinicalTrials.gov ↗ · Breast Cancer, MRD	Observational	Recruiting	2024-01	China
IL-15-Armored CAR-T Therapy in Relapsed or Refractory Multiple Myeloma and Plasma Cell Leukemia NCT07509086 · ClinicalTrials.gov ↗ · Relapsed/Refractory Multiple Myeloma, Plasma Cell Leukemia (PCL)	Phase 2	Recruiting	2025-12	China
Efficacy and Safety Comparison of Short-course Radiotherapy Followed by CapeOX Chemotherapy Plus Toripalimab With or Without Concurrent Surufatinib in Neoadjuvant Therapy for Mid-to-low Localized Rectal Cancer of High-risk Criteria NCT07505472 · ClinicalTrials.gov ↗ · Rectal Cancer	Phase 2/3	Recruiting	2026-02	China
The PRE-VAIL Study NCT07176624 · ClinicalTrials.gov ↗ · ARDS (Moderate or Severe), Prone Position, Enteral Nutrition Feeding	Not applicable	Recruiting	2025-09	China
A Clinical Study on the Efficacy and Safety of Fruquintinib in Combination With PD-1 Monoclonal Antibody and Chidamide in Refractory MSS Metastatic Colorectal Cancer NCT06979908 · ClinicalTrials.gov ↗ · Metastatic Colorectal Cancer Drugs: Chidamide, Fruquintinib, Sintilimab	Phase 2	Recruiting	2025-01	China
Multicenter Single-Arm Study of Ivonescimab (AK112) Combined with Chemotherapy in Pretreated Pleural Mesothelioma NCT06875076 · ClinicalTrials.gov ↗ · Pretreated Pleural Mesothelioma Drug: Ivonescimab	Phase 2	Recruiting	2025-03	China
New Second-Line Combo Therapy for MSS Metastatic Colorectal Cancer NCT07559760 · ClinicalTrials.gov ↗ · Metastatic Colorectal Cancer	Phase 2	Recruiting	2025-11	China
mNEED: a Multicentre, Cluster-randomized, Controlled Trial NCT06827275 · ClinicalTrials.gov ↗ · Feeding, ICU	Not applicable	Recruiting	2025-02	China
Sintilimab Combined With Chemotherapy for Adjuvant Treatment of Mucosal Melanoma After Surgery NCT07400302 · ClinicalTrials.gov ↗ · Mucosal Melanoma, PD-L1 Positive Drugs: Cisplatin, Dacarbazine, Sintilimab	Phase 2	Recruiting	2026-04	China
The Safety and Efficacy of Robotic Assisted Surgery Using Vessel Sealer Extend in Locally Advanced Gastric Cancer NCT06881043 · ClinicalTrials.gov ↗ · Locally Advanced Gastric Cancer, Gastric Adenocarcinoma	Observational	Recruiting	2024-11	China
Efficacy and Safety of CapsuleX Combined With Cisplatin in Platinum-Resistant Recurrent Ovarian Cancer: A Single-Arm Prospective Clinical Study NCT07495384 · ClinicalTrials.gov ↗ · Recurrent Ovarian Cancer, Platinum Resistance	Not applicable	Recruiting	2025-01	China
Single-arm, Prospective Study of the Efficacy and Safety of Paiteling®Antibacterial Liquid in the Treatment of Persistent Cervical HR-HPV Infection NCT07493824 · ClinicalTrials.gov ↗ · Persistent HR-HPV Infection of the Cervix	Phase 4	Recruiting	2025-07	China
Clinical Study on the Diagnosis of Colorectal Lesions by Real-time Artificial Intelligence Assisted Endocytoscopy Combined With Narrow Band Imaging NCT06982885 · ClinicalTrials.gov ↗ · Endocytoscopy	Observational	Recruiting	2025-05	China
Early Tirofiban Administration After Intravenous Thrombolysis in Acute Ischemic Stroke NCT06045156 · ClinicalTrials.gov ↗ · Acute Ischemic Stroke Drug: Tirofiban	Not applicable	Recruiting	2024-04	China
Study of Risk Factors and Prediction of Blood Clots After Lung Cancer Surgery NCT07439991 · ClinicalTrials.gov ↗ · Lung Cancer (Diagnosis), Deep Vein Thrombosis (DVT), Venous Thromboembolism (VTE)	Observational	Recruiting	2024-11	China
Single-arm, Prospective Clinical Trial of Efficacy and Safety of Daphnetin Capsules Combined With TC Regimen for Targeted Maintenance Therapy After Initial Treatment of Stage III-IV Epithelial Ovarian Cancer (RO/R1) NCT07495397 · ClinicalTrials.gov ↗ · Epithelial Ovarian Cancer	Not applicable	Recruiting	2025-11	China
The Diagnostic Value of Subharmonic Imaging Technology Combined With Liver Stiffness and Platelet Count for High-risk Esophageal and Gastric Varices in Patients With Liver Cirrhosis NCT07151885 · ClinicalTrials.gov ↗ · Liver Cirrhosis, Esophageal and Gastric Varices	Not applicable	Recruiting	2025-08	China
The Effect of Different Digestive Tract Reconstruction Methods on Postoperative Quality of Life After Proximal Gastrectomy NCT06929949 · ClinicalTrials.gov ↗ · Gastroesophageal Junction (GEJ) Cancer, Gastric Cancer	Observational	Recruiting	2024-11	China
Safety and Short-term Outcomes of Modular Robotic System for Siewert II/III Gastroesophageal Junction Cancer NCT07790809 · ClinicalTrials.gov ↗ · Siewert Type II/III Gastroesophageal Junction Adenocarcinoma	Not applicable	Recruiting	2026-08	China
Association of Biomarkers and Gastric Antral Motility Index With Feeding Intolerance in Critically Ill Patients NCT07178626 · ClinicalTrials.gov ↗ · Critically Ill Patients Who Are Not Allowed to Eat Orally But Can Initiate Enteral Nutrition Within 48 Hours of ICU	Observational	Recruiting	2025-10	China
Risk Factors and Predictive Model for Inflammatory Polyps in Ureteral Stones NCT07559721 · ClinicalTrials.gov ↗ · Ureteral Calculi	Observational	Recruiting	2018-01	China
Effect of Goal-Oriented Albumin Infusion on Postoperative Complication Management in Gastric Cancer Surgery NCT07119463 · ClinicalTrials.gov ↗ · Postoperative Hypoalbuminemia, Postoperative Complications, Gastric Cancer	Phase 2	Recruiting	2024-10	China
The Impact of Two-Stage Turnbull-Cutait Pull-Through Coloanal Anastomosis on Stoma-free Survival in Low Rectal Anal-preserving Surgery NCT07369531 · ClinicalTrials.gov ↗ · Rectal Cancer, Surgical Anastomosis, Survival , Tumor	Not applicable	Recruiting	2026-03	China
Hypofractionated Radiotherapy NCT06740955 · ClinicalTrials.gov ↗ · Glioblastoma	Not applicable	Recruiting	2024-08	China
Clinical Study on the Accuracy of Real-time AI-assisted Endocytoscopy in the Diagnosis of Colorectal Diminutive Polyps NCT06791408 · ClinicalTrials.gov ↗ · Colorectal Polyp	Observational	Recruiting	2025-02	China
Therapeutic Efficacy and Safety Evaluation of AI in the Management of Diabetes: A RCT Trial NCT06957093 · ClinicalTrials.gov ↗ · Diabetes Mellitus Type 2 (T2DM), Artificial Intelligence (AI)	Not applicable	Recruiting	2025-06	China
Comparison of the Diagnostic Performance of Different Artificial Intelligence Assisted Endocytoscopy for Colorectal Lesions NCT06982872 · ClinicalTrials.gov ↗ · Endocytoscopy	Observational	Recruiting	2025-05	China
Linperlisib Combination With Obinutuzumab Frontline Treatment of Marginal Zone Lymphoma Patients (MZL) NCT06592170 · ClinicalTrials.gov ↗ · Lymphoma	Phase 1/2	Recruiting	2024-08	China
Investigation of Protein Heterogeneity in Extracellular Vesicles Derived From Different Human Blood Circulatory Regions NCT07439965 · ClinicalTrials.gov ↗ · Subarachnoid Aneurysm Hemorrhage, Unruptured Intracranial Aneurysm	Observational	Recruiting	2025-07	China
Nefecon and Ambrisentan in IgA Nephropathy NCT07030894 · ClinicalTrials.gov ↗ · IgA Nephropathy, Chronic Kidney Disease, Proteinuria	Phase 4	Recruiting	2025-09	China
A Prospective Cohort of Patients With Cervical/Intracranial Arteries Stenosis in China NCT06595342 · ClinicalTrials.gov ↗ · Cervical Artery Stenosis, Intracranial Artery Stenosis	Observational	Not yet open	2024-10	China
Total Neoadjuvant Chemoradiotherapy Plus Anti-PD-1 in Subperitoneal Patients With Locally Advanced Rectal CancerPatients With Locally Advanced Rectal Cancer: A Prospective, Single Arm, Exploratory Study NCT05998122 · ClinicalTrials.gov ↗ · Locally Advanced Rectal Cancer, Total Neoadjuvant Treatment, Anti-PD-1	Phase 2	Not yet open	2023-09	China
Personalized KXV01 TCR Lentinvivo Injection as the Therapy for Advanced Solid Tumors NCT07207681 · ClinicalTrials.gov ↗ · Advanced Solid Tumors Drug: KXV01 TCR Lentinvivo	Phase 1	Not yet open	2025-10	China
Hybrid Deep Learning Integrating Multimodal CEUS and Enhanced MRI to Optimize Early-Stage HCC Treatment Decisions NCT07582419 · ClinicalTrials.gov ↗ · Hepatocellular Carcinoma (HCC)	Observational	Not yet open	2026-04	China
Effect of Individualized Catheter Management on Early Removal After Rectal Cancer Surgery NCT07346586 · ClinicalTrials.gov ↗ · Urinary Catheters, Rectal Cancer, Urinary Retention	Not applicable	Not yet open	2026-02	China
Neurological Sequelae in Patients With Acute Carbon Monoxide Poisoning NCT04925297 · ClinicalTrials.gov ↗ · Carbon Monoxide Poisoning	Observational	Not yet open	2021-08	China
RATME Vs LATME in Middle and Low Rectal Cancer NCT06105203 · ClinicalTrials.gov ↗ · Total Mesorectal Excision, Rectal Neoplasms, Robotic Surgical Procedures	Not applicable	Not yet open	2025-11	China
Phase II Trial of Zanubrutinib, Obinutuzumab, Bendamustine (ZGB) as First-Line Therapy for Chronic Lymphocytic Leukemia: A Single-Center Study NCT07003464 · ClinicalTrials.gov ↗ · Chronic Lymphocytic Leukemia Drugs: Bendamustine, Obinutuzumab, Zanubrutinib	Phase 2	Not yet open	2025-06	China
Innovative Probe With Laser on Radial Artery Puncture and Catheterisation in Paediatric NCT07454005 · ClinicalTrials.gov ↗ · Radial Artery Catheterization, Paediatric, Ultrasound Guided	Not applicable	By invitation	2026-02	China
In-plane Versus Real Time Bi-plane Single-operator Laser-assisted With a Innovative T-shaped Probe for Ultrasound-guided Internal Jugular Vein Catheterization:A Randomized Controlled Trial NCT06958731 · ClinicalTrials.gov ↗ · Catheterization, Central Venous, Ultrasound Guided	Not applicable	By invitation	2026-01	China
Efficacy and Safety of DS8201 in Metastatic Breast Cancer's Treatment NCT06914661 · ClinicalTrials.gov ↗ · Breast Cancer Metastatic, Efficacy and Safety	Observational	By invitation	2025-05	China
Establishment of a Sleep and Sleep-disorder Research Cohort in Patients With Neurological Disorders NCT07374393 · ClinicalTrials.gov ↗ · Sleep, Neurology	Observational	By invitation	2026-07	China
The Improvement of Low-dose Esketamine on Postoperative Depression in Patients Undergoing Bariatric Surgery With Preoperative Depression NCT07179913 · ClinicalTrials.gov ↗ · Depressed, Bariatric Surgery Drugs: Dexmedetomidine, Esketamine	Phase 4	Active, closed	2026-05	China
Gemcitabine and Albumin-Bound Paclitaxel Combined With Liposomal Irenotecan (II) With or Without SHR-1701 as Neoadjuvant Therapy for Resectable or Borderline Resectable Pancreatic Cancer NCT07806110 · ClinicalTrials.gov ↗ · Pancreas Ductal Adenocarcinoma Drugs: Gemcitabine, Liposomal Irinotecan, Nab-paclitaxel	Phase 2	Active, closed	2026-07	China
Neoadjuvant Immunotherapy Plus Chemotherapy for Potentially Resectable Stage IIIA/IIIB Non-Small Cell Lung Cancer NCT04326153 · ClinicalTrials.gov ↗ · IIIA Stage Non-small Cell Lung Cancer Drug: Sintilimab	Phase 2	Active, closed	2020-03	China
Antibiotic Exposure on Gut Microbiota and Motility Establishment in Newborns NCT06850896 · ClinicalTrials.gov ↗ · NEC - Necrotizing Enterocolitis	Observational	Active, closed	2025-02	China
A Clinical Study Assessing the Efficacy of Chidamide for CD30-positive Peripheral T-cell Lymphoma (PTCL). NCT06550336 · ClinicalTrials.gov ↗ · Peripheral T Cell Lymphoma Drug: Chidamide	Phase 2	Active, closed	2024-06	China

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

Drugs in The First Hospital of Jilin University trials

18 compounds

Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.

Sintilimab3 Chidamide2 Bendamustine1 Cisplatin1 Dacarbazine1 Dexmedetomidine1 Esketamine1 Fruquintinib1 Gemcitabine1 Ivonescimab1 KXV01 TCR Lentinvivo1 Liposomal Irinotecan1 Nab-paclitaxel1 Obinutuzumab1 SHR-17011 Temozolomide1 Tirofiban1 Zanubrutinib1

Conditions in The First Hospital of Jilin University trials

77 conditions

Rectal Cancer3 Metastatic Colorectal Cancer2Ultrasound Guided2Endocytoscopy2Gastric Cancer2 Breast Cancer1MRD1Relapsed/Refractory Multiple Myeloma1Plasma Cell Leukemia (PCL)1Depressed1Bariatric Surgery1Pancreas Ductal Adenocarcinoma1ARDS (Moderate or Severe)1Prone Position1Enteral Nutrition Feeding1Intensive Care Unit (ICU) Admission1Pretreated Pleural Mesothelioma1Radial Artery Catheterization1Paediatric1IIIA Stage Non-small Cell Lung Cancer1Cervical Artery Stenosis1Intracranial Artery Stenosis1Locally Advanced Rectal Cancer1Total Neoadjuvant Treatment1

By trial register

Register	Trials	Recruiting
Clinical trials in China	47	30

A trial with sites in more than one country appears in each of those registers.

Other sponsors in Rectal Cancer

Sponsor	Trials
Sixth Affiliated Hospital, Sun Yat-sen University	6
Sir Run Run Shaw Hospital	3
Tao Zhang	2
Yanhong Deng	2
Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair	1
Affiliated Cancer Hospital of Shantou University Medical College	1

Sponsors with the most current trials registered for this condition.

Questions about The First Hospital of Jilin University trials

How many clinical trials does The First Hospital of Jilin University sponsor?

The First Hospital of Jilin University is the lead sponsor of 47 current trials on ClinicalTrials.gov in our China register, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.

Are The First Hospital of Jilin University trials recruiting?

Yes. 30 of its 47 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Which drugs is The First Hospital of Jilin University testing?

Its current trials name 18 drugs and biologicals as interventions. The most frequent are Sintilimab (3), Chidamide (2), Bendamustine (1), Cisplatin (1) and Dacarbazine (1). The number in brackets is how many of its trials name each drug.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, lead sponsor, phase, overall status, start date, conditions and intervention names
EU Clinical Trials Information System (CTIS) ↗ EU trial numbers, titles, sponsor, phase, status, therapeutic area and member-state countries

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 26 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.

The First Hospital of Jilin University clinical trials